USANA Health Sciences Projects $925M in 2025 Net Sales, Exceeding Guidance
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3h ago
0mins
Source: seekingalpha
- Sales Guidance Raised: USANA anticipates consolidated net sales of approximately $925 million for fiscal year 2025, surpassing its previous guidance of $920 million and the consensus estimate of $919.85 million, indicating robust performance in its nutritional business.
- Core Business Contribution: The core nutritional segment is expected to generate around $777 million in sales, while Hiya and Rise Wellness are projected to contribute approximately $132 million and $16 million, respectively, highlighting the company's ongoing growth in diversified product lines.
- 2026 Outlook: The company has issued its initial net sales outlook for fiscal year 2026 in the range of $925 million to $1 billion, with USANA expected to contribute $720 million to $765 million, indicating strong future growth potential for Hiya and Rise Wellness as well.
- Positive Market Reaction: USANA's stock rose 1.4% in pre-market trading to $20.14, reflecting investor optimism regarding the company's future performance.
Analyst Views on USNA
About USNA
USANA Health Sciences, Inc. and subsidiaries is a global nutrition, personal health and wellness company that develops and manufactures science-based nutritional and personal care products. Its segments include Direct selling and Hiya direct-to-consumer. The Direct Selling segment develops and manufactures science-based nutritional, personal care and skincare products with a primary focus on promoting long-term health and wellness in various geographic markets worldwide that are distributed through the direct selling channel. The Hiya direct-to-consumer segment is a provider of children’s health and wellness products in the United States that are distributed through the direct-to-consumer channel. Its product line includes USANA Nutritionals Optimizers, Essentials/CellSentials, and Foods. USANA Nutritionals Optimizers products include Proflavanol, CoQuinone 30, and BiOmega-3. Essentials/CellSentials products include USANA CellSentials and HealthPak 100.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
